Abstract:Amyloid A (AA) amyloid deposition in mice is dependent upon isoform-specific effects of the serum amyloid A (SAA) protein. In type A mice, SAA1.1 and SAA2.1 are the major apolipoprotein-SAA isoforms found on high-density lipoproteins. During inflammation, both isoforms are increased 1000-fold, but only SAA1.1 is selectively deposited into amyloid fibrils. Previous studies showed that the CE/J mouse strain is resistant to amyloid induction. This resistance is not due to a deficiency in SAA synthesis, but is probably related to the unusual SAA isoform present. The CE/J mouse has a single acute-phase SAA protein (SAA2.2), which is a composite of the SAA1.1 and SAA2.1, with an amino terminus similar to the nonamyloidogenic SAA2.1. Recently, genetic experiments suggested that the SAA2.2 isoform might provide protection from amyloid deposition. To determine the amyloidogenic potential of the CE/J mouse, we generated SAA adenoviral vectors to express the various isoforms in vitro and in vivo . Purified recombinant SAA proteins demonstrated that SAA1.1 was fibrillogenic in vitro , whereas SAA2.2 was unable to form fibrils. Incubation of increasing concentrations of the nonamyloidogenic SAA2.2 protein with the amyloidogenic SAA1.1 did not inhibit the fibrillogenic nature of SAA1.1, or alter its ability to form extensive fibrils. Injection of the mouse SAA1.1 or SAA2.2 adenoviral vectors into mice resulted in isoform-specific expression of the SAA proteins. Amyloid induction after viral expression of the SAA1.1 protein resulted in the deposition of amyloid fibrils in the CE/J mouse, whereas SAA2.2 expression had no effect. Similar expression of the SAA2.2 protein in C57BL/6 mice did not alter amyloid deposition. These data demonstrate that the failure of the CE/J mouse to deposit amyloid is due to the structural inability of the SAA2.2 to form amyloid fibrils. This mouse provides a unique system to test the amyloidogenic potential of altered SAA proteins and to determine the important structural features of the protein.

Antifungal Activity of Mammalian Serum Amyloid A1 Against Candida Albicans

The Als3 Cell Wall Adhesin Plays a Critical Role in Human Serum Amyloid A1-Induced Cell Death and Aggregation in Candida Albicans.

Serum Amyloid A Exhibits Ph Dependent Antibacterial Action and Contributes to Host Defense Against Staphylococcus Aureus Cutaneous Infection.

Ssa1-targeted Antibody Prevents Host Invasion by Candida Albicans.

Antifungal activity of MAF-1A peptide against Candida albicans

Adenoviral Expression of Murine Serum Amyloid A Proteins to Study Amyloid Fibrillogenesis

Inhibition of Candida albicans in vivo and in vitro by antimicrobial peptides chromogranin A-N12 through microRNA-155/suppressor of cytokine signaling 1 axis

Expression of Mouse Apolipoprotein SAA1.1 in CE/J Mice: Isoform-Specific Effects on Amyloidogenesis

Saps1-3 Antigens in Candida albicans: Differential Modulation Following Exposure to Soluble Proteins, Mammalian Cells, and Infection in Mice

Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection

A Novel Antimicrobial Peptide Derived from Human BPIFA1 Protein Protects Against Candida Albicans Infection.

Inflammation-Dependent Cerebral Deposition of Serum Amyloid A Protein in A Mouse Model of Amyloidosis

Antibody response that protects against disseminated candidiasis

Protective Effect of a Novel Antifungal Peptide Derived from Human Chromogranin a on the Immunity of Mice Infected with Candida Krusei.

Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1

Serum amyloid A1: Structure, function and gene polymorphism

Heat Shock Protein SSA1 Enriched in Hypoxic Secretome of Candida albicans Exerts an Immunomodulatory Effect via Regulating Macrophage Function

Serum Amyloid a Attenuates Tau Phosphorylation in a Systemic Inflammation Model

The Antimicrobial Peptide MAF-1A Acts on the Transcriptional Response of Candida parapsilosis

Emerging Functions Of Serum Amyloid A In Inflammation

Serum amyloid protein A in inflammatory bowel disease: from bench to bedside